News Updates
Scope

Thu, May 28, 2026

1 updates
INKT
9:04 AM

MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteria Landmark advances a first-in-class immune therapy for critical illness where there are no approved mortality-reducing

Trial Start • Phase 2Trial initiation Thu, May 28, 2026minktherapeutics.com

Wed, May 20, 2026

1 updates
INKT
11:07 AM

MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trial Sequential immunotherapy with agenT-797 and N-803, an FDA-approved IL-15 superagonist, Anktiva® may provide impactful clinical combination targeting Coccidioides

Presentation / Abstract • Phase 2ATS poster presentation Wed, May 20, 2026minktherapeutics.com

Fri, May 15, 2026

1 updates
INKT
7:30 AM

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026 AACR and ASGCT presentations showcase durable survival and context-dependent iNKT activity in cancer and inflammatory lung disease

Presentation / Abstract • Phase 2ATS presentation Wed, May 20, 2026minktherapeutics.com

Thu, May 14, 2026

1 updates
INKT
7:30 AM

MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

Randomized Phase 2 trial evaluates off-the-shelf invariant natural killer T (iNKT) cell therapy in patients with acute lung injury and hypoxemic respiratory failure Study initiates in Lviv, Ukraine, in partnership with First Lviv Medical and UNBROKEN Ukraine, expands development into a high-acuity

Trial Start • Phase 2Trial initiation Thu, May 14, 2026minktherapeutics.com

Tue, May 12, 2026

1 updates
INKT
7:35 AM

MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026

iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS — from the same manufacturing donor batch, without genetic engineering Findings underscore the intrinsic biology of iNKT cells and the manufacturing scale for

Presentation / Abstract • Phase 1/2ASGCT poster presentation Thu, May 14, 2026minktherapeutics.com

Fri, May 8, 2026

1 updates

Fri, Apr 17, 2026

1 updates

Fri, Apr 3, 2026

1 updates
INKT
7:30 AM

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

Study will highlight novel iNKT cell-based combinations in checkpoint-refractory disease Data expected to inform immune modulation, treatment sequencing strategy, and clinical durability of response NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a

Presentation / Abstract • Phase 2minktherapeutics.com

Thu, Apr 2, 2026

1 updates

Wed, Apr 1, 2026

1 updates

Tue, Mar 31, 2026

1 updates

Tue, Mar 17, 2026

1 updates

Tue, Mar 10, 2026

1 updates